Medical Information
United States
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRISTIQ® How Supplied/Storage and Handling (desvenlafaxine succinate)

16 HOW SUPPLIED/STORAGE AND HANDLING

PRISTIQ® (desvenlafaxine) extended-release tablets are available as follows:

25 mg, tan, square pyramid tablet debossed with "W" (over) "25" on the flat side

 
NDC 0008-1210-30, bottle of 30 tablets in unit-of-use package

50 mg, light pink, square pyramid tablet debossed with "W" (over) "50" on the flat side

 
NDC 0008-1211-14, bottle of 14 tablets in unit-of-use package
 
NDC 0008-1211-30, bottle of 30 tablets in unit-of-use package
 
NDC 0008-1211-01, bottle of 90 tablets in unit-of-use package
 
NDC 0008-1211-50, 10 blisters of 10 (HUD)

100 mg, reddish-orange, square pyramid tablet debossed with "W" (over) "100" on the flat side

 
NDC 0008-1222-14, bottle of 14 tablets in unit-of-use package
 
NDC 0008-1222-30, bottle of 30 tablets in unit-of-use package
 
NDC 0008-1222-01, bottle of 90 tablets in unit-of-use package
 
NDC 0008-1222-50, 10 blisters of 10 (HUD)

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively.

Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event